The prevalence of anemia in patients with chronic kidney disease

Current Medical Research and Opinion

Volumn 20, Issue 9, 2004, Pages 1501-1510

  McClellan, William ^a   Aronoff, Stephen L ^b   Bolton, W Kline ^c   Hood, Sally ^d   Lorber, Daniel L ^e,f   Tang, K Linda ^g   Tse, Thomas F ^h   Wasserman, Brian ⁱ   Leiserowitz, Marc ^j  

^a EMORY UNIVERSITY   (United States)

^b Endocrine Associates of Dallas   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d Merrimack Valley Dialysis Unit   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g Ortho Biotech Products LP   (United States)

^h St Elizabeth's Hospital   (United States)

ⁱ Chippenham Medical Center   (United States)

^j NEA Research   (United States)

more..

Author keywords

Anemia; Chronic kidney disease; Epoetin alfa; Hemoglobin; Prevalence

Indexed keywords

CREATININE; HEMOGLOBIN;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; FERRITINS; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TRANSFERRIN; UNITED STATES;

EID: 5444255241     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X2763     Document Type: Article

References (27)

1. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-8
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease 2001: evaluation, classification, and stratification. Part 1. Executive summary. Am J Kidney Dis 2002;39(Suppl 1):S17-31
3. US Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003
4. Valderrabano F, Golper T, Muirhead N, et al. Chronic kidney disease: why is current management uncoordinated and suboptimal? Nephrol Dial Transplant 2001;16(Suppl 7):61-4
5. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985;28:1-5
6. Hsu C-Y, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-10
7. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18:50-9
8. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 2001;37(Suppl 1):S182-238
9. Hayashi T, Suzuki A, Shoji T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in pre-dialysis patients with chronic renal failure. Am J Kidney Dis 2000;35:250-6
10. Pickett JL, Theberge DC, Brown WS, et al. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-30
11. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Intern Med 1989;110:108-14
12. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 2001;12:1501-7
13. Obrador GT, Roberts, T, St. Peter WL, et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001;60:1875-84
14. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002;137:479-86
15. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70
16. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A [abstract]
17. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8
18. McClellan W. As to diseases, make a habit of two things - to help, or at least do no harm. J Am Soc Nephrol 2002;13:2817-9 [editorial]
19. Clase CM, Garg AX, Kibert BA. Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 2002;13:2811-6 [letter]
20. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis populations: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-54
21. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34
22. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New Engl J Med 1987;316:73-8
23. Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12
24. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-85
25. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9
26. Collins AJ, Li S, St. Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-73
27. Fink JC, Blahut SA, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348-55